Henry Schein, Inc. $HSIC Stock: Steinberg Asset Management LLC Cuts Stake

Steinberg Asset Management LLC lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 53.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,493 shares of the company’s stock after selling 8,633 shares during the quarter. Steinberg Asset Management LLC’s holdings in Henry Schein were worth $629,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Fifth Third Wealth Advisors LLC bought a new stake in Henry Schein during the third quarter valued at approximately $235,000. Root Financial Partners LLC bought a new position in Henry Schein in the third quarter worth approximately $50,000. Nisa Investment Advisors LLC boosted its stake in shares of Henry Schein by 1.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 33,512 shares of the company’s stock worth $2,814,000 after acquiring an additional 538 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Henry Schein during the 3rd quarter worth $462,000. Finally, V Square Quantitative Management LLC boosted its stake in shares of Henry Schein by 18.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 4,026 shares of the company’s stock worth $338,000 after acquiring an additional 614 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a research report on Wednesday, August 5th. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Piper Sandler lifted their target price on Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Citigroup reissued a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Finally, BMO Capital Markets began coverage on Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Moderate Buy” and an average target price of $93.27.

Henry Schein Price Performance

NASDAQ HSIC opened at $84.88 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60. Henry Schein, Inc. has a 12 month low of $62.44 and a 12 month high of $92.18. The stock has a market cap of $9.46 billion, a price-to-earnings ratio of 24.75, a PEG ratio of 1.53 and a beta of 0.84. The company’s 50 day moving average is $86.53 and its two-hundred day moving average is $81.09.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, research analysts anticipate that Henry Schein, Inc. will post 5.36 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.